Search Results 2661-2670 of 17712 for rheumatoid arthritis

  1. Study Using Curcumin and Piperine in Reducing Inflammation for Ureteral Stent-Induced Symptoms - Mayo Clinic

    Taking any of the following drugs at the time of study participation: epidermal growth factor receptor inhibitor, topoisomerase 1 inhibitor (camptothecin ...

  2. Arthroscopy - Doctors & Departments - Mayo Clinic

    April 2, 2024. Related. Arthritis · Baker cyst · Hip dysplasia · Hip labral tear · Knee pain · Patellofemoral pain syndrome · Swollen knee · Thumb arthritis ...

  3. Publications - Robert R. Cima, M.D. - Mayo Clinic

    Wanta BT, Glasgow AE, Habermann EB, Kor DJ, Cima RR, Berbari EF, Curry TB, Brown MJ, Hyder JA. Operating Room Traffic as a Modifiable Risk Factor for Surgical ...

  4. Publications - Megan N. Wasson, D.O. - Mayo Clinic

    Is Hysterectomy a Risk Factor for Urinary Retention? A Retrospective Matched Case Control Study. J Minim Invasive Gynecol. 2020 Nov - Dec; 27 (7):1598-1602 ...

  5. Ulnar Ligament Ultrasound Stress Test - Mayo Clinic

    Prior or current history of elbow joint pain, injury, or surgery such as elbow joint arthritis, prior/current elbow ulnar collateral ligament injury that ...

  6. Virotherapy Clinical Trials - Mayo Clinic Research

    The purpose of this study is to look at the safety and immune response to a vaccine used in patients previously treated for HER2 (human epidermal growth factor ...

  7. A Study to Evaluate the Effectiveness and Safety of rAd-IFN Administered With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma - Mayo Clinic

    Hematopoietic growth factor, at least 14 days from last dose; or; Study drug, 30 days or 5 half-lives, whichever is longer, from last dose. Patient ...

  8. S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma - Mayo Clinic

    ... factor support within 14 days prior to registration; Platelets >= 50,000 cells/mm^3 for patients who have bone marrow plasmacytosis < 50% or >= 30,000 cells ...

  9. Publications - Sujay A. Vora, M.D. - Mayo Clinic

    Patient Specific Characteristics Are an Important Factor That Determines the Risk of Acute Grade >/= 2 Rectal Toxicity in Patients Treated for Prostate ...

  10. A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma - Mayo Clinic

    ... factor support, or medically significant need for intervention. For subjects with presumptive evidence of transformation based on clinical assessment of ...